Gonococcal OMV Vaccine Homogeneous LOS Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gonococcal OMV-based vaccines face challenges in eliciting effective immunogenic responses against heterologous strains of Neisseria gonorrhoeae due to phase variability of LOS biosynthesis genes, leading to heterogeneous LOS structures and reduced batch-to-batch consistency.
Innovation Solution
Genetically engineering Neisseria gonorrhoeae to produce OMVs with consistent, homogeneous LOS structures by rendering the phase variability of LOS glycosyl transferase genes non-variable and detoxifying the LOS, resulting in OMVs with oligosaccharide alpha-chains elongating from Hep I with at least four hexose monosaccharides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If OMVs are derived from wild-type Neisseria gonorrhoeae with phase variable LOS biosynthesis genes, then the vaccine can be produced using standard strains, but the LOS structures become heterogeneous and batch-to-batch consistency is reduced
Solution Approach 1:
The patent applies parameter changes by modifying the genetic parameters of the LOS biosynthesis genes (specifically the lgt genes) to render them non-phase variable. This involves changing the expression pattern of these genes from variable to constant, thereby producing homogeneous LOS structures across batches while maintaining ease of manufacture using engineered strains.
Solution Approach 2:
The patent applies local quality by making specific localized changes to the LOS structure itself - specifically elongating the oligosaccharide alpha-chain from Hep I to have at least four hexose monosaccharides. This localized structural modification ensures consistency in the critical immunogenic region while allowing other aspects of the OMV to remain manageable for production.
2Ease of manufacture
If OMVs are derived from wild-type Neisseria gonorrhoeae, then production is straightforward, but cross-strain bactericidal antibody responses are reduced due to phase variability
Solution Approach 1:
The patent changes the genetic parameter of phase variability in LOS biosynthesis genes to achieve consistent LOS structures that elicit reliable cross-strain bactericidal antibody responses. The engineered strains produce homogeneous LOS with elongated alpha-chains that provide broad immunogenicity while maintaining ease of production.
Solution Approach 2:
The patent applies preliminary action by pre-engineering the Neisseria gonorrhoeae strains to have non-phase variable LOS biosynthesis genes before OMV production. This preliminary genetic modification ensures that the LOS structures will be consistent and immunogenic from the start, eliminating the need for complex sorting or selection processes later.
3Manufacturing precision
If LOS structure is made homogeneous through genetic engineering, then batch-to-batch consistency improves, but the complexity of the production system increases
Solution Approach 1:
The patent changes the genetic parameters of LOS biosynthesis genes to achieve homogeneity, but this is accomplished through relatively simple point mutations or deletions in the lgt genes rather than complex multi-gene engineering. The resulting system maintains acceptable complexity levels while achieving the desired manufacturing precision.
Data Source
AI summary
The present invention provides immunogenic compositions and vaccines comprising isolated gonococcal outer membrane vesicles (OMVs). Said isolated gonococcal OMVs display lipooligosaccharide (LOS) glycan structures comprising an oligosaccharide alpha-chain elongating from Hep I having at least four hexose monosaccharides (4Hex or 5Hex) and wherein said LOS is detoxified. The present invention relates to the use of said immunogenic compositions and vaccines in medicine and, more particularly, the use of said immunogenic compositions and vaccines in immunizing a subject against Neisseria gonorrhoeae infection.